Furthermore, clinical trials evaluating a combination of DNAse-1 and tPA as stroke therapy vs. conventional tPA alone are needed to confirm the utility of NETs as therapeutic targets in stroke. The gene discussed is DNASE1; the disease is stroke disorder.